Holen Sie sich die Stockscreener-App
0.00
100.00%
-15.02
Schlusskurs vom Vortag:
$15.02
Offen:
$0
24-Stunden-Volumen:
0
Relative Volume:
0.00
Marktkapitalisierung:
$1.48B
Einnahmen:
$11.40B
Nettoeinkommen (Verlust:
$-95.73M
KGV:
0.00
EPS:
-2.45
Netto-Cashflow:
$-64.37M
1W Leistung:
-100.00%
1M Leistung:
-100.00%
6M Leistung:
-100.00%
1J Leistung:
-100.00%
1-Tages-Spanne:
$0.00
$0.00
1-Wochen-Bereich:
$0.00
$0.00
52-Wochen-Spanne:
$0.00
$15.29
Definium Therapeutics Inc Stock (MNMD) Company Profile
Firmenname
Definium Therapeutics Inc
Sektor
Branche
Telefon
212-220-6633
Adresse
ONE WORLD TRADE CENTER, NEW YORK
Compare MNMD vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MNMD
Definium Therapeutics Inc
|
0.00 | 1.48B | 11.40B | -95.73M | -64.37M | -2.45 |
VRTX
Vertex Pharmaceuticals Inc
|
436.83 | 111.05B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
742.73 | 79.01B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
793.73 | 50.08B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
310.76 | 41.15B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
309.88 | 34.67B | 5.36B | 287.73M | 924.18M | 2.5229 |
Definium Therapeutics Inc Stock (MNMD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-17 | Eingeleitet | Stifel | Buy |
| 2026-04-10 | Eingeleitet | Piper Sandler | Overweight |
| 2026-02-24 | Eingeleitet | Wolfe Research | Outperform |
| 2026-01-30 | Eingeleitet | Jefferies | Buy |
| 2025-10-13 | Eingeleitet | Needham | Buy |
| 2025-08-04 | Fortgesetzt | Oppenheimer | Outperform |
| 2025-01-28 | Eingeleitet | Evercore ISI | Outperform |
| 2024-12-20 | Eingeleitet | Chardan Capital Markets | Buy |
| 2024-10-14 | Fortgesetzt | Leerink Partners | Outperform |
| 2024-07-24 | Eingeleitet | ROTH MKM | Buy |
| 2024-05-29 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-04-15 | Eingeleitet | Leerink Partners | Outperform |
| 2023-12-05 | Eingeleitet | Canaccord Genuity | Buy |
| 2022-12-09 | Fortgesetzt | ROTH Capital | Buy |
| 2022-11-16 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-08-26 | Eingeleitet | Oppenheimer | Outperform |
| 2022-08-10 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-05-04 | Eingeleitet | ROTH Capital | Buy |
| 2021-06-28 | Eingeleitet | Maxim Group | Buy |
Alle ansehen
Definium Therapeutics Inc Aktie (MNMD) Neueste Nachrichten
DFTX Maintained by Leerink Partners -- Price Target Raised to $3 - GuruFocus
DFTX News Today | Why did Definium Therapeutics stock go up today? - MarketBeat
Definium Therapeutics (DFTX) Stock Gains After Hours: Here's What's Driving The Move - Benzinga
Definium Therapeutics Announces New Employee Inducement GrantsApril 20, 2026 - BioSpace
LifeSci Capital Maintains Definium Therapeutics(DFTX.US) With Buy Rating, Raises Target Price to $38 - Moomoo
Definium Therapeutics Anxiety Drug A Multi-Billion Opportunity: Analyst - MSN
Definium Therapeutics (DFTX) Short Interest & Short Float | Updated Apr 2026 - MarketBeat
Definium Therapeutics (DFTX) Stock Soars to New Heights on Trump’s Psychedelic Research Order - MEXC Exchange
Definium Therapeutics stock hits 52-week high at 25.63 USD - Investing.com
Definium Therapeutics (DFTX) Stock Hits 52-Week High as Trump Backs Psychedelic Medicine Research - CoinCentral
Definium Therapeutics (DFTX) Stock Soars to New Heights on Trump's Psychedelic Research Order - Blockonomi
Psychedelic Pharmaceutical Companies' Shares Rise Following Executive Order -- Update - Moomoo
Enveric BioSciences Surges Over 90%, Other Psychedelic Stocks Soar In Monday Pre-Market: What's Going On? - Benzinga
Cybin stands out as the most undervalued psychedelic stock as Trump signs on faster PTSD research - Seeking Alpha
Psychedelic drug makers rally as Trump orders FDA to expedite reviews - Yahoo Finance
Psychedelic stocks rally after Trump orders faster PTSD research; Compass Pathways, Atai lead gains - Seeking Alpha
DFTX Vs CMPS: Which Stock Has More Upside From Trump’s New Psychedelic Therapy Push? - Stocktwits
Definium Therapeutics (DFTX) Is Up 5.3% After White House Signals Support For Psychedelic Research - simplywall.st
Definium Therapeutics (DFTX) Stock Climbs Following White House Psychedelic Policy Shift - MEXC
Definium Therapeutics (DFTX) Stock Rises as White House Moves on Psychedelic Treatments | MEXC News - MEXC Exchange
Definium Therapeutics (DFTX) Stock Rises as White House Moves on Psychedelic Treatments - MEXC
symbol__ Stock Quote Price and Forecast - CNN
Definium Therapeutics supports White House executive order on mental health innovation, committed to developing psychedelic treatments for mental health - marketscreener.com
Definium Therapeutics Supports White House Executive Order On Mental Health Innovation, Committed To Developing Psychedelic Treatments For Mental Health - TradingView
Definium Therapeutics Applauds White House Executive Order to Accelerate Mental Health Innovation and Expand Access to Psychedelic Medical Treatments - The Joplin Globe
Why Definium Therapeutics’ LSD-Based Drug Has Wall Street Watching 2026 - TechStock²
Trump signs executive order on psychedelics (ATAI:NASDAQ) - Seeking Alpha
Trump Trade: President to sign order on psychedelic used for PTSD - Yahoo Finance
Is It Too Late To Consider Definium Therapeutics (DFTX) After Its Strong 1 Year Run? - Yahoo Finance
Definium: 'Strong Buy' Maintained On Several Anticipated 2026 Milestones (NASDAQ:DFTX) - Seeking Alpha
DFTX Initiates Coverage On Stifel -- Rating Set to Buy - GuruFocus
Can an LSD candidate do for anxiety what Spravato did for depression? - Pharma Voice
Stifel Initiates Definium Therapeutics at Buy With $30 Price Target - marketscreener.com
Definium Therapeutics Conference Slot Tests Psychedelic Phase III And Funding Story - Sahm
DFTX Maintains Buy Rating by Canaccord Genuity -- Price Target R - GuruFocus
Stifel initiates Definium stock with buy rating on anxiety drug - Investing.com UK
Stifel initiates Definium stock with buy rating on anxiety drug By Investing.com - Investing.com Australia
Definium Therapeutics Teases 3 Phase III DT120 Readouts in 2026, Starting Late Q2 MDD Data - MarketBeat
Definium Therapeutics Price Target Raised to $38.00/Share From $25.00 by Canaccord Genuity - Moomoo
Shroom stocks rise as Trump is said to sign executive order on psychedelic drug - Seeking Alpha
Top Definium Therapeutics (DFTX) Competitors 2026 - MarketBeat
Definium Therapeutics (NASDAQ:DFTX) Sets New 1-Year HighStill a Buy? - MarketBeat
DFTX Options Chain — NASDAQ:DFTX - TradingView
DFTX Options Volatility — NASDAQ:DFTX - TradingView
Definium Therapeutics Sees Insider Stock Selling - 富途牛牛
DFTX: Definium Therapeutics, Inc.Income Statment - Zacks Investment Research
All News for DFTX : Definium Therapeutics, Inc. - Zacks Investment Research
DFTX: Piper Sandler Initiates Coverage with Overweight Rating | - GuruFocus
Definium Therapeutics stock hits 52-week high at 21.99 USD - Investing.com
Definium Therapeutics stock hits 52-week high at 21.99 USD By Investing.com - Investing.com UK
Finanzdaten der Definium Therapeutics Inc-Aktie (MNMD)
Umsatz
Nettogewinn
Free Cashflow
ENV
Definium Therapeutics Inc-Aktie (MNMD) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Sullivan Mark | Chief Legal Officer |
Mar 25 '26 |
Sale |
18.47 |
10,702 |
197,666 |
271,079 |
| Barrow Robert | Chief Executive Officer |
Mar 25 '26 |
Sale |
18.47 |
24,431 |
451,241 |
752,454 |
1.09%
0.42%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):